Whole exome sequencing reveals the order of genetic changes during malignant transformation and metastasis in a single patient with NF1-plexiform neurofibroma

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4201-4211

  Hirbe, Angela C ^a   Dahiya, Sonika ^a   Miller, Christopher A ^b   Li, Tiandao ^b   Fulton, Robert S ^b   Zhang, Xiaochun ^a   McDonald, Sandra ^a   DeSchryver, Katherine ^a   Duncavage, Eric J ^a   Walrath, Jessica ^c,d   Reilly, Karlyne M ^c,d   Abel, Haley J ^e   Pekmezci, Melike ^e   Perry, Arie ^a,e   Ley, Timothy J ^b   Gutmann, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Department of Genetics   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SPECTRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; COPY NUMBER VARIATION; EXOME; GENE AMPLIFICATION; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MALIGNANT TRANSFORMATION; MOLECULAR EVOLUTION; MOUSE; NEUROFIBROMA; NEUROFIBROMATOSIS TYPE 1; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TISSUE MICROARRAY; TP53 GENE; ANIMAL; BIOPSY; CANCER TRANSPLANTATION; CELL TRANSFORMATION; CHEMISTRY; DISEASE COURSE; DNA MICROARRAY; DNA SEQUENCE; GENETIC VARIATION; GENETICS; METASTASIS; MUTATION; NERVE SHEATH TUMOR; TUMOR SUPPRESSOR GENE;

ANIMALS; BIOPSY; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; EXOME; GENES, P53; GENETIC VARIATION; HUMANS; MICE; MUTATION; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NERVE SHEATH NEOPLASMS; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMATOSIS 1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SEQUENCE ANALYSIS, DNA; SPECTRIN;

EID: 84942864200     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3049     Document Type: Article

References (63)

1. Arun D, Gutmann DH. Recent advances in neurofibromatosis type 1. Curr Opin Neurol 2004;17:101-5.
2. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014;13:834-43.
3. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007;44:81-8.
4. Upadhyaya M, Spurlock G, Monem B, Thomas N, Friedrich RE, Kluwe L, et al. Germline and somatic NF1 gene mutations in plexiform neurofibromas. Hum Mutat 2008;29:E103-11.
5. Rasmussen SA, Overman J, Thomson SA, Colman SD, Abernathy CR, Trimpert RE, et al. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer 2000;28:425-31.
6. Perry A, Roth KA, Banerjee R, Fuller CE, Gutmann DH. NF1 deletions in S- 100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol 2001;159:57-61.
7. Reuss DE, HabelA, Hagenlocher C, Mucha J, AckermannU, Tessmer C, et al. Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. Acta Neuropathol 2014;127:565-72.
8. Bottillo I, Ahlquist T, Brekke H, Danielsen SA, van den Berg E, Mertens F, et al. Germline and somatic NF1 mutations in sporadic and NF1- associated malignant peripheral nerve sheath tumours. J Pathol 2009; 217:693-701.
9. Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow. Cell 2008;135:437-48.
10. Zheng H, Chang L, Patel N, Yang J, Lowe L, Burns DK, et al. Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell 2008;13:117-28.
11. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296: 920-2.
12. Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 2008;13:105-16.
13. Brossier NM, Carroll SL. Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system. Brain Res Bull 2012;88:58-71.
14. Watson MA, Perry A, Tihan T, Prayson RA, Guha A, Bridge J, et al. Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol 2004;14:297-303.
15. Riddle ND, Gorden L, Rojiani MV, Hakam A, Rojiani AM. CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration. Int J Clin Exp Pathol 2010;3:515-21.
16. Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T, et al. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res 2011;17:1924-34.
17. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009;1: 236-48.
18. Upadhyaya M, Spurlock G, Thomas L, Thomas NS, Richards M, Mautner VF, et al. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associatedmalignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Hum Mutat 2012;33:763-76.
19. Danielsen SA, Lind GE, Kolberg M, Holand M, Bjerkehagen B, Sundby Hall K, et al. Methylated RASSF1A inmalignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. Neuro Oncol 2015;17:63-9.
20. Park GH, Lee SJ, Yim H, Han JH, Kim HJ, Sohn YB, et al. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions. Oncol Rep 2014;32:1347-54.
21. Perry A, Kunz SN, Fuller CE, Banerjee R, Marley EF, Liapis H, et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 2002;61:702-9.
22. Holtkamp N, Mautner VF, Friedrich RE, Harder A, Hartmann C, Theallier- Janko A, et al. Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathol 2004;107:159-68.
23. Fang Y, Elahi A, Denley RC, Rao PH, Brennan MF, Jhanwar SC. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1. Anticancer Res 2009; 29:1255-62.
24. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. Neurofibromatosis 1988;1:172-8.
25. Li H, Durbin R. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics 2009;25:1754-60.
26. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25: 2078-9.
27. Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 2012;28:311-7.
28. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012;22:568-76.
29. Saunders CT, WongWS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012;28:1811-7.
30. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20:1297-303.
31. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 2009;25: 2865-71.
32. Hirbe AC, Pekmezci M, Dahiya S, Apicelli AJ, Van Tine BA, Perry A, et al. BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro Oncol 2014;16: 466-7.
33. Uhlmann EJ, Li W, Scheidenhelm DK, Gau CL, Tamanoi F, Gutmann DH. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia 2004;47:180-8.
34. Turbyville TJ, Gursel DB, Tuskan RG, Walrath JC, Lipschultz CA, Lockett SJ, et al. Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRDdependent manner. Mol Cancer Ther 2010;9:1234-43.
35. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000;26:109-13.
36. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004;64:8604-12.
37. Warrington NM, Gianino SM, Jackson E, Goldhoff P, Garbow JR, Piwnica- Worms D, et al. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res 2010;70: 5717-27.
38. Spurlock G, Knight SJ, Thomas N, Kiehl TR, Guha A, Upadhyaya M. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol 2010;136:1869-80.
39. Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM, et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarraybased comparative genomic hybridization. Clin Cancer Res 2008; 14:1015-24.
40. Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006; 66:2584-91.
41. Levy P, Vidaud D, Leroy K, Laurendeau I, Wechsler J, Bolasco G, et al. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Mol Cancer 2004;3:20.
42. Skotheim RI, Kallioniemi A, Bjerkhagen B, Mertens F, Brekke HR, Monni O, et al. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol 2003;21:4586-91.
43. Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ, et al. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 1994;10:250-5.
44. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999;286:2172-6.
45. Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF. Mouse tumor model for neurofibromatosis type 1. Science 1999;286: 2176-9.
46. Lothe RA, Smith-Sorensen B, Hektoen M, Stenwig AE, Mandahl N, Saeter G, et al. Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer 2001;30:202-6.
47. Rahrmann EP, Moriarity BS, Otto GM, Watson AL, Choi K, Collins MH, et al. Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis. Am J Pathol 2014;184:2082-98.
48. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 1999;155:1879-84.
49. Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, Gronchi A, et al. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-relatedmalignant peripheral nerve sheath tumors. Clin Cancer Res 2003;9:4132-8.
50. Beert E, Brems H, Daniels B, De Wever I, Van Calenbergh F, Schoenaers J, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer 2011;50: 1021-32.
51. Storlazzi CT, Brekke HR, Mandahl N, Brosjo O, Smeland S, Lothe RA, et al. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J Pathol 2006;209:492-500.
52. Alaggio R, Turrini R, Boldrin D, Merlo A, Gambini C, Ferrari A, et al. Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). PLoS One 2013;8:e80456.
53. Athanasoula K, Gogas H, Polonifi K, Vaiopoulos AG, Polyzos A, Mantzourani M. Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. Cancer Lett 2014;347: 175-82.
54. Kolettas E, Muir HI, Barrett JC, Hardingham TE. Chondrocyte phenotype and cell survival are regulated by culture conditions and by specific cytokines through the expression of Sox-9 transcription factor. Rheumatology 2001;40:1146-56.
55. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
56. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
57. Lupo A, Cesaro E, Montano G, Zurlo D, Izzo P, Costanzo P. KRAB-Zinc finger proteins: a repressor family displaying multiple biological functions. Curr Genomics 2013;14:268-78.
58. Zhang R, Zhang C, Zhao Q, Li D. Spectrin: structure, function and disease. Sci China Life Sci 2013;56:1076-85.
59. Armbrust KR, Wang X, Hathorn TJ, Cramer SW, Chen G, Zu T, et al.Mutant beta-III spectrin causes mGluR1alpha mislocalization and functional deficits in a mouse model of spinocerebellar ataxia type 5. J Neurosci 2014;34:9891-904.
60. Salcedo-Sicilia L, Granell S, Jovic M, Sicart A, Mato E, Johannes L, et al. betaIII spectrin regulates the structural integrity and the secretory protein transport of the Golgi complex. J Biol Chem 2013;288: 2157-66.
61. Stankewich MC, Tse WT, Peters LL, Ch'ng Y, John KM, Stabach PR, et al. A widely expressed betaIII spectrin associated with Golgi and cytoplasmic vesicles. Proc Natl Acad Sci U S A 1998;95: 14158-63.
62. Perkins EM, Clarkson YL, Sabatier N, Longhurst DM, Millward CP, Jack J, et al. Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans. J Neurosci 2010;30:4857-67.
63. Scoles DR, Huynh DP, Morcos PA, Coulsell ER, Robinson NG, Tamanoi F, et al. Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin. Nat Genet 1998;18:354-9.